Holen Sie sich die Stockscreener-App
2.88
2.86%
0.08
Schlusskurs vom Vortag:
$2.80
Offen:
$2.9
24-Stunden-Volumen:
348.33K
Relative Volume:
1.94
Marktkapitalisierung:
$15.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.33M
KGV:
-0.1027
EPS:
-28.0369
Netto-Cashflow:
$-24.28M
1W Leistung:
+6.67%
1M Leistung:
+37.80%
6M Leistung:
-24.80%
1J Leistung:
-80.24%
1-Tages-Spanne:
$2.81
$2.96
1-Wochen-Bereich:
$2.60
$2.96
52-Wochen-Spanne:
$1.79
$24.00
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.88 | 15.37M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech Inc (MBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moleculin Biotech Inc (MBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Moleculin Biotech Inc (MBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Moleculin Biotech Inc (MBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Moleculin Biotech Inc (MBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Moleculin Biotech Inc (MBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Moleculin Biotech Inc (MBRX) Institutional Confidence - TradingKey
Moleculin Biotech Inc (MBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Moleculin Biotech (MBRX) Sees Modest Uptick as Stock Consolidates Near SupportVWAP Bounce - newsline.com
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nano-cap Moleculin Biotech approaches key leukemia trial data unblinding - MSN
Moleculin Biotech Announces Positive Market Assessment for Annamycin in Relapsed/Refractory AML (R/R AML) – Key Clinical Advantages and Unmet Needs Highlighted - Minichart
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy - TipRanks
Moleculin Biotech Reports Strong Physician Interest in Annamycin for R/R AML Treatment, Highlighting Unmet Needs and Positive Market Assessment - Quiver Quantitative
Moleculin market study shows strong physician, payer interest in Annamycin for R/R AML - TradingView
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML - The Manila Times
Strong physician interest in Annamycin reported by Moleculin (NASDAQ: MBRX) - Stock Titan
Leukemia drug Annamycin wins doctor and insurer support in new survey - Stock Titan
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor What This Means Segment - marketscreener.com
Moleculin Biotech (MBRX) Holds Steady at $2.46 – Key Levels in FocusOvervalued Signals - newsline.com
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor 'What This Means” Segment - The Manila Times
Leukemia trial of Annamycin hits 45-patient milestone, mid‑2026 data ahead - Stock Titan
Moleculin Biotech (MBRX) Holds Near Key Support as Modest Uptick Signals Cautious TradingTrend Following Picks - The Legal Advocate
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO - TipRanks
Moleculin Presents ASCO Data Showing No Detectable Cardiotoxicity with Annamycin at High Exposure - TradingView
Moleculin Biotech (MBRX) shares ASCO data on Annamycin cardiac safety and MIRACLE trial - Stock Titan
Moleculin Presents ASCO 2026 Data Demonstrating No - GlobeNewswire
Moleculin Biotech (MBRX) Edges Higher on Modest Volume: Support Holds Near $2.65Early Entry Signals - newsline.com
Moleculin Biotech (MBRX) Holds Steady at $2.73 Amid Consolidation PhaseHigh Reward Trades - newsline.com
Moleculin Biotech (MBRX) Rises 3.27%: Breaking Above Support with Resistance in SightPCR Spike - thelegaladvocate.com
Moleculin Biotech’s MIRACLE Trial Data Exceeds Historical Benchmarks for AML Treatment - geneonline.com
Moleculin Biotech Releases Updated Investor Information Presentation - TipRanks
Moleculin Biotech, Inc. Files SEC Form 8-K and Releases May 2026 Investor Presentation - Minichart
Moleculin Biotech (NASDAQ: MBRX) posts new May 2026 investor presentation - Stock Titan
Moleculin Biotech (MBRX) Holds Steady at $2.39 as Trading Remains FlatVOLD Alert - newsline.com
Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN
Why Did MBRX Stock Plummet Over 25% Today? - MSN
Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan
Moleculin presents cardiac safety data for Annamycin at ASCO By Investing.com - Investing.com South Africa
Moleculin's Annamycin shows no heart toxicity in trials, advancing AML cancer treatment. - Pluang
Moleculin presents cardiac safety data for Annamycin at ASCO - Investing.com
Moleculin Biotech, Inc. Presents Cardiac Safety Data for Annamycin at 2026 ASCO Annual Meeting - Quiver Quantitative
Pooled trials of cancer drug Annamycin find no cardiotoxicity signal - Stock Titan
Why did MBRX stock climb 14% today? - MSN
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech stock (US60855L2034): Maxim Group keeps Buy rating - AD HOC NEWS
Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX - Moomoo
Moleculin Biotech: Runway to Support Planned Operations Into 3Q 2026 >MBRX - Moomoo
What Does GF Score 27/100 Say About Moleculin Biotech (MBRX) Aft - GuruFocus
Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Q1 2026 Financial Results and Clinical Trial Updates - Minichart
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):